|
|
Blood, 15 March 2004, Vol. 103, No. 6, pp. 2325-2331.
Prepublished online as a Blood First Edition Paper on November 26, 2003; DOI 10.1182/blood-2003-09-3287.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Mignon L. Loh,
Shashaank Vattikuti,
Suzanne Schubbert,
Melissa G. Reynolds,
Elaine Carlson,
Kenneth H. Lieuw,
Jennifer W. Cheng,
Connie M. Lee,
David Stokoe,
Jeannette M. Bonifas,
Nicole P. Curtiss,
Jason Gotlib,
Soheil Meshinchi,
Michelle M. Le Beau,
Peter D. Emanuel, and
Kevin M. Shannon
From the Department of Pediatrics, University of California, San Francisco; Comprehensive Cancer Center, University of California, San Francisco; Program in Human Genetics, University of California, San Francisco; Cancer Research Institute, University of California, San Francisco; Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; Department of Pediatrics, University of Washington, Seattle; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham.
The PTPN11 gene encodes SHP-2 (Src homology 2 domaincontaining protein tyrosine Phosphatase), a nonreceptor tyrosine protein tyrosine phosphatase (PTPase) that relays signals from activated growth factor receptors to p21Ras (Ras) and other signaling molecules. Mutations in PTPN11 cause Noonan syndrome (NS), a developmental disorder characterized by cardiac and skeletal defects. NS is also associated with a spectrum of hematologic disorders, including juvenile myelomonocytic leukemia (JMML). To test the hypothesis that PTPN11 mutations might contribute to myeloid leukemogenesis, we screened the entire coding region for mutations in 51 JMML specimens and in selected exons from 60 patients with other myeloid malignancies. Missense mutations in PTPN11 were detected in 16 of 49 JMML specimens from patients without NS, but they were less common in other myeloid malignancies. RAS, NF1, and PTPN11 mutations are largely mutually exclusive in JMML, which suggests that mutant SHP-2 proteins deregulate myeloid growth through Ras. However, although Ba/F3 cells engineered to express leukemia-associated SHP-2 proteins cells showed enhanced growth factorindependent survival, biochemical analysis failed to demonstrate hyperactivation of the Ras effectors extracellular-regulated kinase (ERK) or Akt. We conclude that SHP-2 is an important cellular PTPase that is mutated in myeloid malignancies. Further investigation is required to clarify how these mutant proteins interact with Ras and other effectors to deregulate myeloid growth.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Mutated SHP and AML in leukemias
- Gen-Sheng Feng
Blood 2004 103: 1982-1983.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G.-M. Zou and A. Maitra
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration
Mol. Cancer Ther.,
July 1, 2008;
7(7):
2012 - 2021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Eminaga and A. M. Bennett
Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRP{alpha} and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation
J. Biol. Chem.,
May 30, 2008;
283(22):
15328 - 15338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Braun and K. Shannon
Targeting Ras in Myeloid Leukemias
Clin. Cancer Res.,
April 15, 2008;
14(8):
2249 - 2252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu
Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL
J. Biol. Chem.,
December 14, 2007;
282(50):
36463 - 36473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, E. Diaz-Flores, G. Li, Z. Wang, Z. Kang, E. Haviernikova, S. Rowe, C.-K. Qu, W. Tse, K. M. Shannon, et al.
Abnormal hematopoiesis in Gab2 mutant mice
Blood,
July 1, 2007;
110(1):
116 - 124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle
The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration
Cancer Res.,
May 1, 2007;
67(9):
4278 - 4286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Chan and G.-S. Feng
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Blood,
February 1, 2007;
109(3):
862 - 867.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lindsey, W. Huang, H. Wang, E. Horvath, C. Zhu, and E. A. Eklund
Activation of SHP2 Protein-tyrosine Phosphatase Increases HoxA10-induced Repression of the Genes Encoding gp91PHOX and p67PHOX
J. Biol. Chem.,
January 26, 2007;
282(4):
2237 - 2249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Blood,
January 15, 2007;
109(2):
778 - 785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Braun, J. A. Archard, J. A. G. Van Ziffle, D. A. Tuveson, T. E. Jacks, and K. Shannon
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo
Blood,
September 15, 2006;
108(6):
2041 - 2044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Huang, G. Saberwal, E. Horvath, C. Zhu, S. Lindsey, and E. A. Eklund
Leukemia-Associated, Constitutively Active Mutants of SHP2 Protein Tyrosine Phosphatase Inhibit NF1 Transcriptional Activation by the Interferon Consensus Sequence Binding Protein.
Mol. Cell. Biol.,
September 1, 2006;
26(17):
6311 - 6332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Wang, Z. Li, R. Ding, G. D. Frank, T. Senbonmatsu, E. J. Landon, T. Inagami, and Z. J. Zhao
Antagonism or Synergism: ROLE OF TYROSINE PHOSPHATASES SHP-1 AND SHP-2 IN GROWTH FACTOR SIGNALING
J. Biol. Chem.,
August 4, 2006;
281(31):
21878 - 21883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Charest, E. W. Wilker, M. E. McLaughlin, K. Lane, R. Gowda, S. Coven, K. McMahon, S. Kovach, Y. Feng, M. B. Yaffe, et al.
ROS Fusion Tyrosine Kinase Activates a SH2 Domain-Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice.
Cancer Res.,
August 1, 2006;
66(15):
7473 - 7481.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Kontaridis, K. D. Swanson, F. S. David, D. Barford, and B. G. Neel
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
J. Biol. Chem.,
March 10, 2006;
281(10):
6785 - 6792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-M. Yu, H. Daino, J. Chen, K. D. Bunting, and C.-K. Qu
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling
J. Biol. Chem.,
March 3, 2006;
281(9):
5426 - 5434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yuan, W.-M. Yu, M. Xu, and C.-K. Qu
SHP-2 Phosphatase Regulates DNA Damage-induced Apoptosis and G2/M Arrest in Catalytically Dependent and Independent Manners, Respectively
J. Biol. Chem.,
December 30, 2005;
280(52):
42701 - 42706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Schubbert, M. Zenker, S. L. Rowe, S. Boll, C. Klein, I. van der Burgt, L. Musante, H. Nguyen, B. West, G. Bollag, et al.
Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
1602 - 1602.
[Abstract]
|
 |
|

|
 |

|
 |
 
A J Bauer and C A Stratakis
The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis
J. Med. Genet.,
November 1, 2005;
42(11):
801 - 810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, Z. He, Y. Liang, Q. Lu, Y. Fang, X. Gan, et al.
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia
Blood,
November 1, 2005;
106(9):
3142 - 3149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Sharma, B. A. Zehnbauer, M. A. Watson, and D. H. Gutmann
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma
Neurology,
October 25, 2005;
65(8):
1335 - 1336.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. P. Kratz, C. M. Niemeyer, R. P. Castleberry, M. Cetin, E. Bergstrasser, P. D. Emanuel, H. Hasle, G. Kardos, C. Klein, S. Kojima, et al.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
Blood,
September 15, 2005;
106(6):
2183 - 2185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Keilhack, F. S. David, M. McGregor, L. C. Cantley, and B. G. Neel
Diverse Biochemical Properties of Shp2 Mutants: IMPLICATIONS FOR DISEASE PHENOTYPES
J. Biol. Chem.,
September 2, 2005;
280(35):
30984 - 30993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Schubbert, K. Lieuw, S. L. Rowe, C. M. Lee, X. Li, M. L. Loh, D. W. Clapp, and K. M. Shannon
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Blood,
July 1, 2005;
106(1):
311 - 317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Illmer, C. Thiede, A. Fredersdorf, S. Stadler, A. Neubauer, G. Ehninger, and M. Schaich
Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts
Clin. Cancer Res.,
May 1, 2005;
11(9):
3217 - 3224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Chan, M. B. Leedy, V. Munugalavadla, C. S. Voorhorst, Y. Li, M. Yu, and R. Kapur
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
Blood,
May 1, 2005;
105(9):
3737 - 3742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Chen, M. Levis, P. Brown, K.-T. Kim, J. Allebach, and D. Small
FLT3/ITD Mutation Signaling Includes Suppression of SHP-1
J. Biol. Chem.,
February 18, 2005;
280(7):
5361 - 5369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bentires-Alj, J. G. Paez, F. S. David, H. Keilhack, B. Halmos, K. Naoki, J. M. Maris, A. Richardson, A. Bardelli, D. J. Sugarbaker, et al.
Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
Cancer Res.,
December 15, 2004;
64(24):
8816 - 8820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Loh and K. M. Shannon
A "Ras-in-ALL" model of signaling?
Blood,
July 15, 2004;
104(2):
297 - 298.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tartaglia, S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, M. Arico, et al.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
Blood,
July 15, 2004;
104(2):
307 - 313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Yoshida, T. Hasegawa, Y. Hasegawa, T. Nagai, E. Kinoshita, Y. Tanaka, H. Kanegane, K. Ohyama, T. Onishi, K. Hanew, et al.
Protein-Tyrosine Phosphatase, Nonreceptor Type 11 Mutation Analysis and Clinical Assessment in 45 Patients with Noonan Syndrome
J. Clin. Endocrinol. Metab.,
July 1, 2004;
89(7):
3359 - 3364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |